scholarly journals Inferring perturbation profiles of cancer samples

2021 ◽  
Author(s):  
Martin Pirkl ◽  
Niko Beerenwinkel
Keyword(s):  
Indirect Evidence ◽  
R Package ◽  
The Cancer Genome Atlas ◽  
Supplementary Information ◽  
Patient Specific ◽  
Driver Genes ◽  
Cancer Driver ◽  
Molecular Alterations ◽  
Incomplete Coverage ◽  
Gene Perturbations

Abstract Motivation Cancer is one of the most prevalent diseases in the world. Tumors arise due to important genes changing their activity, e.g. when inhibited or over-expressed. But these gene perturbations are difficult to observe directly. Molecular profiles of tumors can provide indirect evidence of gene perturbations. However, inferring perturbation profiles from molecular alterations is challenging due to error-prone molecular measurements and incomplete coverage of all possible molecular causes of gene perturbations. Results We have developed a novel mathematical method to analyze cancer driver genes and their patient-specific perturbation profiles. We combine genetic aberrations with gene expression data in a causal network derived across patients to infer unobserved perturbations. We show that our method can predict perturbations in simulations, CRISPR perturbation screens and breast cancer samples from The Cancer Genome Atlas. Availability and implementation The method is available as the R-package nempi at https://github.com/cbg-ethz/nempi and http://bioconductor.org/packages/nempi. Supplementary information Supplementary data are available at Bioinformatics online.

scholarly journals Inferring perturbation profiles of cancer samples

2020 ◽  
Author(s):  
Martin Pirkl ◽  
Niko Beerenwinkel
Keyword(s):  
Indirect Evidence ◽  
R Package ◽  
The Cancer Genome Atlas ◽  
Patient Specific ◽  
Driver Genes ◽  
Cancer Driver ◽  
Molecular Alterations ◽  
Incomplete Coverage ◽  
Cancer Genome Atlas ◽  
Gene Perturbations

AbstractMotivationCancer is one of the most prevalent diseases in the world. Tumors arise due to important genes changing their activity, e.g., when inhibited or over-expressed. But these gene perturbations are difficult to observe directly. Molecular profiles of tumors can provide indirect evidence of gene perturbations. However, inferring perturbation profiles from molecular alterations is challenging due to error-prone molecular measurements and incomplete coverage of all possible molecular causes of gene perturbations.ResultsWe have developed a novel mathematical method to analyze cancer driver genes and their patient-specific perturbation profiles. We combine genetic aberrations with gene expression data in a causal network derived across patients to infer unobserved perturbations. We show that our method can predict perturbations in simulations, CRISPR perturbation screens, and breast cancer samples from The Cancer Genome Atlas.AvailabilityThe method is available as the R-package nempi at https://github.com/cbg-ethz/[email protected], [email protected]

scholarly journals An integrative analysis of the age-associated multi-omic landscape across cancers

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kasit Chatsirisupachai ◽  
Tom Lesluyes ◽  
Luminita Paraoan ◽  
Peter Van Loo ◽  
João Pedro de Magalhães
Keyword(s):  
The Cancer Genome Atlas ◽  
Driver Genes ◽  
Cancer Driver ◽  
Molecular Alterations ◽  
Age Related ◽  
Incidence And Mortality ◽  
Cancer Genome Atlas ◽  
Cancer Types ◽  
Using Data ◽  
Transcriptomic Changes

AbstractAge is the most important risk factor for cancer, as cancer incidence and mortality increase with age. However, how molecular alterations in tumours differ among patients of different age remains largely unexplored. Here, using data from The Cancer Genome Atlas, we comprehensively characterise genomic, transcriptomic and epigenetic alterations in relation to patients’ age across cancer types. We show that tumours from older patients present an overall increase in genomic instability, somatic copy-number alterations (SCNAs) and somatic mutations. Age-associated SCNAs and mutations are identified in several cancer-driver genes across different cancer types. The largest age-related genomic differences are found in gliomas and endometrial cancer. We identify age-related global transcriptomic changes and demonstrate that these genes are in part regulated by age-associated DNA methylation changes. This study provides a comprehensive, multi-omics view of age-associated alterations in cancer and underscores age as an important factor to consider in cancer research and clinical practice.

scholarly journals An Integrative Analysis of the Age-Associated Genomic, Transcriptomic and Epigenetic Landscape across Cancers

2020 ◽  
Author(s):  
Kasit Chatsirisupachai ◽  
Tom Lesluyes ◽  
Luminita Paraoan ◽  
Peter Van Loo ◽  
João Pedro de Magalhães
Keyword(s):  
The Cancer Genome Atlas ◽  
Driver Genes ◽  
Cancer Driver ◽  
Molecular Alterations ◽  
Age Related ◽  
Incidence And Mortality ◽  
Cancer Genome Atlas ◽  
Cancer Types ◽  
Using Data ◽  
Transcriptomic Changes

AbstractAge is the most important risk factor for cancer, as cancer incidence and mortality increase with age. However, how molecular alterations in tumours differ among patients of different age remains largely unexplored. Here, using data from The Cancer Genome Atlas, we comprehensively characterised genomic, transcriptomic and epigenetic alterations in relation to patients’ age across cancer types. We showed that tumours from older patients present an overall increase in genomic instability, somatic copy-number alterations (SCNAs) and somatic mutations. Age-associated SCNAs and mutations were identified in several cancer-driver genes across different cancer types. The largest age-related genomic differences were found in gliomas and endometrial cancer. We identified age-related global transcriptomic changes and demonstrated that these genes are controlled by age-associated DNA methylation changes. This study provides a comprehensive view of age-associated alterations in cancer and underscores age as an important factor to consider in cancer research and clinical practice.

scholarly journals Ranking cancer drivers via betweenness-based outlier detection and random walks

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Cesim Erten ◽  
Aissa Houdjedj ◽  
Hilal Kazan
Keyword(s):  
Cancer Genomics ◽  
Interaction Network ◽  
Molecular Data ◽  
Alternative Methods ◽  
Patient Specific ◽  
Cancer Genes ◽  
Driver Genes ◽  
Cancer Driver ◽  
Protein Protein Interaction ◽  
Genomic Studies

Abstract Background Recent cancer genomic studies have generated detailed molecular data on a large number of cancer patients. A key remaining problem in cancer genomics is the identification of driver genes. Results We propose BetweenNet, a computational approach that integrates genomic data with a protein-protein interaction network to identify cancer driver genes. BetweenNet utilizes a measure based on betweenness centrality on patient specific networks to identify the so-called outlier genes that correspond to dysregulated genes for each patient. Setting up the relationship between the mutated genes and the outliers through a bipartite graph, it employs a random-walk process on the graph, which provides the final prioritization of the mutated genes. We compare BetweenNet against state-of-the art cancer gene prioritization methods on lung, breast, and pan-cancer datasets. Conclusions Our evaluations show that BetweenNet is better at recovering known cancer genes based on multiple reference databases. Additionally, we show that the GO terms and the reference pathways enriched in BetweenNet ranked genes and those that are enriched in known cancer genes overlap significantly when compared to the overlaps achieved by the rankings of the alternative methods.

scholarly journals Systematic identification of mutations and copy number alterations associated with cancer patient prognosis

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Joan C Smith ◽  
Jason M Sheltzer
Keyword(s):  
Copy Number ◽  
Meta Analysis ◽  
Gene Copy Number ◽  
Gene Copy ◽  
Driver Genes ◽  
Cancer Driver ◽  
Molecular Alterations ◽  
Patient Prognosis ◽  
Almost All ◽  
Systematic Identification

Successful treatment decisions in cancer depend on the accurate assessment of patient risk. To improve our understanding of the molecular alterations that underlie deadly malignancies, we analyzed the genomic profiles of 17,879 tumors from patients with known outcomes. We find that mutations in almost all cancer driver genes contain remarkably little information on patient prognosis. However, CNAs in these same driver genes harbor significant prognostic power. Focal CNAs are associated with worse outcomes than broad alterations, and CNAs in many driver genes remain prognostic when controlling for stage, grade, TP53 status, and total aneuploidy. By performing a meta-analysis across independent patient cohorts, we identify robust prognostic biomarkers in specific cancer types, and we demonstrate that a subset of these alterations also confer specific therapeutic vulnerabilities. In total, our analysis establishes a comprehensive resource for cancer biomarker identification and underscores the importance of gene copy number profiling in assessing clinical risk.

scholarly journals OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers

2020 ◽  
Vol 49 (D1) ◽  
pp. D1289-D1301 ◽  
Author(s):  
Tao Wang ◽  
Shasha Ruan ◽  
Xiaolu Zhao ◽  
Xiaohui Shi ◽  
Huajing Teng ◽  
...  
Keyword(s):  
Cancer Genome ◽  
The Cancer Genome Atlas ◽  
Driver Mutations ◽  
Cancer Genes ◽  
Driver Genes ◽  
Cancer Driver ◽  
Cancer Cell Population ◽  
Cancer Types ◽  
Neutral Mutations ◽  
Analysis Platform

Abstract The prevalence of neutral mutations in cancer cell population impedes the distinguishing of cancer-causing driver mutations from passenger mutations. To systematically prioritize the oncogenic ability of somatic mutations and cancer genes, we constructed a useful platform, OncoVar (https://oncovar.org/), which employed published bioinformatics algorithms and incorporated known driver events to identify driver mutations and driver genes. We identified 20 162 cancer driver mutations, 814 driver genes and 2360 pathogenic pathways with high-confidence by reanalyzing 10 769 exomes from 33 cancer types in The Cancer Genome Atlas (TCGA) and 1942 genomes from 18 cancer types in International Cancer Genome Consortium (ICGC). OncoVar provides four points of view, ‘Mutation’, ‘Gene’, ‘Pathway’ and ‘Cancer’, to help researchers to visualize the relationships between cancers and driver variants. Importantly, identification of actionable driver alterations provides promising druggable targets and repurposing opportunities of combinational therapies. OncoVar provides a user-friendly interface for browsing, searching and downloading somatic driver mutations, driver genes and pathogenic pathways in various cancer types. This platform will facilitate the identification of cancer drivers across individual cancer cohorts and helps to rank mutations or genes for better decision-making among clinical oncologists, cancer researchers and the broad scientific community interested in cancer precision medicine.

scholarly journals Somatic Selection Distinguishes Oncogenes and Tumor Suppressor Genes

2019 ◽  
Author(s):  
Pramod Chandrashekar ◽  
Navid Ahmadinejad ◽  
Junwen Wang ◽  
Aleksandar Sekulic ◽  
Jan B Egan ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor Genes ◽  
Tumor Biology ◽  
Supplementary Information ◽  
Cancer Type ◽  
Driver Genes ◽  
Suppressor Genes ◽  
Cancer Driver ◽  
Cancer Driver Genes ◽  
Somatic Selection

Abstract Motivation Functions of cancer driver genes vary substantially across tissues and organs. Distinguishing passenger genes (PGs), oncogenes (OGs) and tumor suppressor genes (TSGs) for each cancer type is critical for understanding tumor biology and identifying clinically actionable targets. Although many computational tools are available to predict putative cancer driver genes, resources for context-aware classifications of OGs and TSGs are limited. Results We show that the direction and magnitude of somatic selection of protein-coding mutations are significantly different for PGs, OGs and TSGs. Based on these patterns, we develop a new method (genes under selection in tumors, GUST) to discover OGs and TSGs in a cancer-type specific manner. GUST shows a high accuracy (92%) when evaluated via strict cross-validations. Its application to 10,172 tumor exomes found known and novel cancer drivers with high tissue-specificities. In 11 out of 13 OGs shared among multiple cancer types, we found functional domains selectively engaged in different cancers, suggesting differences in disease mechanisms. Availability An R implementation of the GUST algorithm is available at https://github.com/liliulab/gust. A database with pre-computed results is available at https://liliulab.shinyapps.io/gust. Supplementary information Supplementary data are available at Bioinformatics online.

scholarly journals PRODIGY: personalized prioritization of driver genes

2019 ◽  
Author(s):  
Gal Dinstag ◽  
Ron Shamir
Keyword(s):  
Drug Targets ◽  
Somatic Mutations ◽  
Supplementary Information ◽  
Gene Identification ◽  
Centrality Measures ◽  
Patient Specific ◽  
Driver Gene ◽  
Tree Model ◽  
Driver Genes ◽  
The Impact

Abstract Motivation Evolution of cancer is driven by few somatic mutations that disrupt cellular processes, causing abnormal proliferation and tumor development, while most somatic mutations have no impact on progression. Distinguishing those mutated genes that drive tumorigenesis in a patient is a primary goal in cancer therapy: Knowledge of these genes and the pathways on which they operate can illuminate disease mechanisms and indicate potential therapies and drug targets. Current research focuses mainly on cohort-level driver gene identification, but patient-specific driver gene identification remains a challenge. Methods We developed a new algorithm for patient-specific ranking of driver genes. The algorithm, called PRODIGY, analyzes the expression and mutation profiles of the patient along with data on known pathways and protein-protein interactions. Prodigy quantifies the impact of each mutated gene on every deregulated pathway using the prize collecting Steiner tree model. Mutated genes are ranked by their aggregated impact on all deregulated pathways. Results In testing on five TCGA cancer cohorts spanning >2500 patients and comparison to validated driver genes, Prodigy outperformed extant methods and ranking based on network centrality measures. Our results pinpoint the pleiotropic effect of driver genes and show that Prodigy is capable of identifying even very rare drivers. Hence, Prodigy takes a step further towards personalized medicine and treatment. Availability The Prodigy R package is available at: https://github.com/Shamir-Lab/PRODIGY. Supplementary information Supplementary data are available at Bioinformatics online.

scholarly journals Colorectal cancer driver genes identified by patient specific comparison of cytogenetic microarray

Genomics Data ◽  
2014 ◽  
Vol 2 ◽  
pp. 29-31 ◽  
Author(s):  
Mohammad Azhar Aziz ◽  
Sathish Periyasamy ◽  
Zeyad Yousef ◽  
Ahmad Deeb ◽  
Majed AlOtaibi
Keyword(s):  
Colorectal Cancer ◽  
Patient Specific ◽  
Driver Genes ◽  
Cancer Driver ◽  
Cancer Driver Genes ◽  
Specific Comparison

scholarly journals DriverGroup: A novel method for identifying driver gene groups

2020 ◽  
Author(s):  
Vu VH Pham ◽  
Lin Liu ◽  
Cameron P Bracken ◽  
Gregory J Goodall ◽  
Jiuyong Li ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Single Gene ◽  
Gene Interaction ◽  
Computational Method ◽  
Supplementary Information ◽  
Driver Gene ◽  
Driver Genes ◽  
Cancer Driver ◽  
Critical Nodes ◽  
Novel Method

AbstractMotivationIdentifying cancer driver genes is a key task in cancer informatics. Most exisiting methods are focused on individual cancer drivers which regulate biological processes leading to cancer. However, the effect of a single gene may not be sufficient to drive cancer progression. Here, we hypothesise that there are driver gene groups that work in concert to regulate cancer and we develop a novel computational method to detect those driver gene groups.ResultsWe develop a novel method named DriverGroup to detect driver gene groups by using gene expression and gene interaction data. The proposed method has three stages: (1) Constructing the gene network, (2) Discovering critical nodes of the constructed network, and (3) Identifying driver gene groups based on the discovered critical nodes. Before evaluating the performance of DriverGroup in detecting cancer driver groups, we firstly assess its performance in detecting the influence of gene groups, a key step of DriverGroup. The application of DriverGroup to DREAM4 data demonstrates that it is more effective than other methods in detecting the regulation of gene groups. We then apply DriverGroup to the BRCA dataset to identify coding and non-coding driver groups for breast cancer. The identified driver groups are promising as several group members are confirmed to be related to cancer in literature. We further use the predicted driver groups in survival analysis and the results show that the survival curves of patient subpopulations classified using the predicted driver groups are significantly differentiated, indicating the usefulness of DriverGroup.Availability and implementationDriverGroup is available at https://github.com/pvvhoang/[email protected] informationSupplementary data are available at Bioinformatics online.

Sign in / Sign up

Export Citation Format

Share Document